BioSpace News Archive

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the “Company” or “IntelGenx”), a leader in pharmaceutical films, today announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response Letter (“CRL”) that it recently received from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm

Authorization of compassionate use granted by the Italian authorities, aided by RedHill’s strategic partner, Cosmo Pharmaceuticals N.V. (SIX: COPN) Approximately 160 patients with life-threatening clinical manifestations planned to be treated in three major hospitals in northern Italy A compassionate use program is ongoing in Israel where opaganib has been administered to the first patient at a leading hospital Discussions ongoing in the U.S. and other countries RedHill preparing for

MaxCyte, a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company and provide a business update at the upcoming Solebury Trout Virtual Global Healthcare Series.

Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company’s operational and clinical activities.

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has closed a $12M Series B1 financing round led by Research Corporation Technologies (RCT).

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom

Novo Nordisk announced the European Commission has granted marketing authorization for Rybelsus®,, for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycemic control as an adjunct to diet and exercise.

Emmes announced that Heather Hill, Dr. Adam Mendizabal and Dr. Nilay Shah have been promoted to vice president.

ProtoKinetix, Incorporated (ecently announced filing for patent protection for new applications of its AAGP® (PKX-001) molecule, announces preliminary results in efficacy and safety for use in treating Dry Eye Disease (DED).

In response to continued public health concerns about in-person gatherings given the coronavirus/COVID-19 outbreak, the Board of Directors of Lantheus Holding, Inc. (the “Company”) (NASDAQ:LNTH) has determined to change the format of the company’s 2020 Annual Meeting of Stockholders scheduled for Thursday, April 23, 2020 at 11:00 a.m. (Eastern Time) from in-person to virtual-only.